Accession Number:

ADA599044

Title:

Evaluation of Carbohydrate-Derived Fulvic Acid (CHD-FA) as a Topical Broad-Spectrum Antimicrobial for Drug-Resistant Wound Infections

Descriptive Note:

Annual rept. 30 Sep 2012-29 Sep 2013

Corporate Author:

RUTGERS - THE STATE UNIV NEWARK NJ

Personal Author(s):

Report Date:

2013-10-01

Pagination or Media Count:

22.0

Abstract:

In the first year of this research contract we demonstrated the antimicrobial properties of Carbohydrate-Derived Fulvic Acid CHD-FA against a broad collection of multi-drug resistant bacterial and fungal pathogens commonly associated with wound infections. We completed the objectives in specific aim 1 of the award statement of work by determining the in vitro susceptibility of CHD-FA against a collection of multi-drug resistant Acinetobacter baumanii, Pseudomonas aeruginosa, carbapenamase-resistant Klebsiella pneumoniae, Enterococcus faecium, Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus MRSA, Escherichia coli, Enterobacter spp., other clinically important species. as well as azole resistant fungal pathogens Candida spp., Aspergillus fumigatus and polyene-resistant non-fumigatus Aspergillus species, Fusarium species and Zygomycetes. We have also established a cutaneous wound infection model in rats with MRSA and Pseudomonas aeruginosa to assess CHD-FA as a potent topical agent to prevent drug resistant wound infections and promote healing as part of specific aim 2 of the research contract. Daily topical applications of CHD-FA were placed on the cutaneous wounds in rats at 4 and 24 H post infection for up to 10 days. Wound size and wound bacterial burdens were measured to assess the treatment efficacy of CHD-FA. CHD-FA treated animals had improved wound healing and reduced bacterial burden.

Subject Categories:

  • Anatomy and Physiology
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE